ONT Stock Overview
Engages in the research, development, manufacture, and commercialization of a nanopore based sequencing platform that allows the real-time analysis of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) in the Americas, Europe, the Middle East, Africa, India, and the Asia Pacific.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Oxford Nanopore Technologies plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£1.42 |
| 52 Week High | UK£2.29 |
| 52 Week Low | UK£0.85 |
| Beta | 0.79 |
| 11 Month Change | 18.14% |
| 3 Month Change | 39.76% |
| 1 Year Change | -34.68% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -76.82% |
Recent News & Updates
Recent updates
Revenues Tell The Story For Oxford Nanopore Technologies plc (LON:ONT) As Its Stock Soars 30%
Jul 23
What You Can Learn From Oxford Nanopore Technologies plc's (LON:ONT) P/SAfter Its 25% Share Price Crash
Apr 26Oxford Nanopore Technologies plc (LON:ONT) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Mar 09Oxford Nanopore Technologies plc's (LON:ONT) Share Price Matching Investor Opinion
Mar 08Companies Like Oxford Nanopore Technologies (LON:ONT) Are In A Position To Invest In Growth
Jul 12With Oxford Nanopore Technologies plc (LON:ONT) It Looks Like You'll Get What You Pay For
May 14Companies Like Oxford Nanopore Technologies (LON:ONT) Are In A Position To Invest In Growth
Apr 06Companies Like Oxford Nanopore Technologies (LON:ONT) Can Afford To Invest In Growth
Dec 22New Forecasts: Here's What Analysts Think The Future Holds For Oxford Nanopore Technologies plc (LON:ONT)
Sep 19We Think Oxford Nanopore Technologies (LON:ONT) Can Easily Afford To Drive Business Growth
Sep 16Shareholder Returns
| ONT | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | 21.1% | 10.9% | -2.4% |
| 1Y | -34.7% | -25.7% | 7.6% |
Return vs Industry: ONT underperformed the UK Life Sciences industry which returned -25.7% over the past year.
Return vs Market: ONT underperformed the UK Market which returned 7.6% over the past year.
Price Volatility
| ONT volatility | |
|---|---|
| ONT Average Weekly Movement | 8.5% |
| Life Sciences Industry Average Movement | 7.4% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in GB Market | 9.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: ONT's share price has been volatile over the past 3 months.
Volatility Over Time: ONT's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 1,281 | Gordon Sanghera | nanoporetech.com |
Oxford Nanopore Technologies plc engages in the research, development, manufacture, and commercialization of a nanopore based sequencing platform that allows the real-time analysis of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) in the Americas, Europe, the Middle East, Africa, India, and the Asia Pacific. The company operates in Life Science Research Tools and Covid Testing segments. It offers MinION, a portable device for DNA and RNA; GridION, a flexible and self-contained benchtop nanopore sequencer to run and analyse up to five MinION or Flongle flow cells; MinION Mk 1C, a nano pore-based sequencer with analysis software and connectivity for self-contained and portable sequencing; Flongle, an adapter for MinION or GridION that enables DNA sequencing or cDNA sequencing on smaller and single-use flow cells; and PromethION 2 Solo, a sequencer for two PromethION flow cells.
Oxford Nanopore Technologies plc Fundamentals Summary
| ONT fundamental statistics | |
|---|---|
| Market cap | UK£1.34b |
| Earnings (TTM) | -UK£159.06m |
| Revenue (TTM) | UK£167.75m |
8.0x
P/S Ratio-8.4x
P/E RatioIs ONT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ONT income statement (TTM) | |
|---|---|
| Revenue | UK£167.75m |
| Cost of Revenue | UK£77.35m |
| Gross Profit | UK£90.40m |
| Other Expenses | UK£249.46m |
| Earnings | -UK£159.06m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.17 |
| Gross Margin | 53.89% |
| Net Profit Margin | -94.82% |
| Debt/Equity Ratio | 0% |
How did ONT perform over the long term?
See historical performance and comparison